Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. - Wikidata - awgldk - TriplyDB

Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.

Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.

http://www.wikidata.org/entity/Q30419537

about

Combating Tuberculosis Infection: A Forbidding Challenge Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB Biochemical and structural characterization of mycobacterial aspartyl-tRNA synthetase AspS, a promising TB drug target New anti-tuberculosis drugs and regimens: 2015 update Repurposing clinically approved cephalosporins for tuberculosis therapy Tuberculosis therapy for 2016 and beyond.Insights into the pharmacokinetic properties of antitubercular drugs.SQ109, a new drug lead for Chagas disease.In vitro activity of AZD5847 against geographically diverse clinical isolates of Mycobacterium tuberculosis.Multitarget drug discovery for tuberculosis and other infectious diseases.The mycobacterial cell envelope-lipids Investigational antimicrobial agents of 2013.The cell envelope glycoconjugates of Mycobacterium tuberculosis Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis.RND transporters protect Corynebacterium glutamicum from antibiotics by assembling the outer membrane.A Nano-MgO and Ionic Liquid-Catalyzed 'Green' Synthesis Protocol for the Development of Adamantyl-Imidazolo-Thiadiazoles as Anti-Tuberculosis Agents Targeting Sterol 14α-Demethylase (CYP51).New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics.Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.Screening the Pathogen Box for Identification of Candida albicans Biofilm Inhibitors Antiinfectives targeting enzymes and the proton motive force.Targeting the trehalose utilization pathways of Mycobacterium tuberculosis Advances in Drug Discovery and Development for Pediatric Tuberculosis.Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3 High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.Indoleamides are active against drug-resistant Mycobacterium tuberculosis Synergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds In Vitro.Discovery of a Structurally Unique Small Molecule that Inhibits Protein Synthesis Prospects for new antibiotics: a molecule-centered perspective.Resistance in tuberculosis: what do we know and where can we go?Trends in discovery of new drugs for tuberculosis therapy.The future for early-stage tuberculosis drug discovery Novel drug combination for Mycobacterium abscessus disease therapy identified in a Drosophila infection model.The anti-tuberculosis agents under development and the challenges ahead.Synthetic investigational new drugs for the treatment of tuberculosis.The paradigm shift to end tuberculosis. Are we ready to assume the changes?Emerging drugs and alternative possibilities in the treatment of tuberculosis.Inhibition of Leishmania mexicana Growth by the Tuberculosis Drug SQ109 Mycobacterial cell wall biosynthesis: a multifaceted antibiotic target.Drug Resistance Mechanisms in Mycobacterium tuberculosis.Detection and treatment of Trypanosoma cruzi: a patent review (2011-2015).

P2860

Q26750683-1236022C-C182-4F69-81EC-63746D29927F Q28484670-27DA892F-DE81-4EB2-BEF2-E28D68D96EA2 Q28545065-EDBD71C8-2FC1-4EAA-87F3-C5B1212D3A27 Q28596775-F09713A1-6C82-433D-8E59-550D578D7889 Q28828720-88AC8494-71C4-409B-9045-CA4744E1FC3A Q30248788-E38761ED-33E7-47EA-8A11-4801C5D4CBE7 Q30251497-4E20CD6B-0912-4F44-BF71-A7E4ACD68F1A Q30626912-4D5F7880-F706-4B46-B21D-DE385B37D8E8 Q33798527-D6C29C1A-C589-4EE5-98E7-CA4758DA8B11 Q33854785-63FB41D5-6354-40A6-8EE3-F21D7D30073D Q34355375-4749580A-276A-411F-89D5-1E7B6D33C211 Q34375204-6AF317CC-C1D3-47E6-9D8D-92C99183B269 Q34423962-90FA56B1-A6CA-4A6C-B4B1-0EDFD42E9013 Q34596427-D76B1F9E-50CA-4E5D-A767-0D1D0F62E02B Q34870110-329F86E4-BCB4-4F02-8A81-8034CD3FA0F8 Q35808907-2DE58EE7-6412-424C-8855-583D7E5268D3 Q36057012-8D9135A6-4F33-45C0-BCDE-090E24D47E28 Q36094215-ABD25F20-B555-46EE-94A0-7665A016CEF8 Q36177985-767B418B-618B-423F-8021-AA2CAA3C66AC Q36419761-02A0952C-BA1A-453C-9E37-A4A3EE672D99 Q36629840-BF91F52D-24FF-4A22-9E0D-48A5265E2AAD Q37134041-CD0BFBA2-C062-437B-BF95-65B7CE65A625 Q37203793-FF5B8544-21BE-4366-9F4B-639D2A380089 Q37507802-A307102B-523F-40A9-811C-306CA4AD38B2 Q37541307-6854EFD6-F92E-4226-AB63-92705C7F71D2 Q37720810-BBAF0BD1-F5DD-4E96-BE51-913E078447B6 Q37724398-F856110E-5E9C-4BA4-97C6-F6B1A00D948E Q38113689-7B67F7BF-AD59-4F7A-A88B-FA5D3B3EC46C Q38124261-03BBB527-D48F-43DC-BA75-487C1EDBBC23 Q38237221-6610C1C2-9723-4330-9DFA-06ED982982FC Q38358621-A7E9E2E8-A30C-42C0-9907-86E66520670E Q38441471-9876E0FE-CD61-4789-BC77-135727E52810 Q38617197-431D5EDA-F003-4959-BDE7-06CECCDDCE1E Q38635790-03D94CB8-BC6C-4214-BDC2-0709D881CF13 Q38676708-874274B1-4AD3-4E42-A95F-0B0F166D351F Q38724073-AE92B1F0-2969-4478-A697-2DCD5BE78CF6 Q38755807-1F4355D6-EDE3-4A44-9D92-8BF8B332957B Q38782638-0FACBBCE-2BDE-44A1-8A52-C2136989E4C1 Q38792870-38FD5227-3C72-420F-B7D4-ECA4933D7821 Q38845466-3C6ADC53-4CAF-4E55-BE21-3BB241C92CBD

P2860

Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.

http://www.wikidata.org/entity/Q30419537

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Discovery and development of S ...... h a novel mechanism of action.

@ast

Discovery and development of S ...... h a novel mechanism of action.

@en

type

label

Discovery and development of S ...... h a novel mechanism of action.

@ast

Discovery and development of S ...... h a novel mechanism of action.

@en

prefLabel

Discovery and development of S ...... h a novel mechanism of action.

@ast

Discovery and development of S ...... h a novel mechanism of action.

@en

P1433

Q30419537-1B7FBC96-F3ED-4F36-A524-4E599A64A70D

P1476

Q30419537-25CDA20D-AE90-4D30-9A93-ED25F8104237

P2093

Q30419537-01EFC2BC-9936-4117-AF9C-13E220083707

Q30419537-0C9967DE-B7DF-4762-BA1A-2CA0723B3048

Q30419537-7DA87950-E596-479F-AC27-626566E724AE

Q30419537-9D532D9E-EFD2-4872-83C5-28704DBE5161

P2860

Q30419537-0244C70C-0D38-41DF-9475-F9198D507F79

Q30419537-02D2FD0C-13AB-414D-9486-BD932BBC6FEB

Q30419537-04330A8B-BA7C-4B05-AFD1-458B1380CFFD

Q30419537-07E9CE37-5764-4600-A062-7B7398D2B4D5

Q30419537-0AC08990-A0AE-4175-9725-59E1077ECBF0

Q30419537-13624D00-C3B0-4961-86B0-52090B286540

Q30419537-151BDA34-9115-49A2-A889-662136BB0F3E

Q30419537-1A7065A6-33A7-4C87-A2D6-4D829056FEF7

Q30419537-2242E4F7-4D70-4DCD-B1A7-A9D2EB5868DD

Q30419537-23DC2EA1-EB2C-437C-9605-90B70C5F197F

P304

Q30419537-E869DE00-3166-4D1E-AC35-8FB8EF6DDCE9

P31

Q30419537-AEE2CB7F-124C-49B2-A6D4-BE279ABD73B9

P356

Q30419537-E3AF137A-064E-4A35-A1AA-51A0CD3F41DD

P433

Q30419537-703967F4-E524-4463-9634-FF2084D1A38C

P478

Q30419537-FFEE5B87-69A4-492C-97DB-5FEBE8985AD6

P50

Q30419537-FF788248-F72D-4363-BEA1-141ADC6A886A

P577

Q30419537-E6DAA503-6644-4F7F-9A44-D786E0CF54B3

P5875

Q30419537-C2325CC6-3E13-4BB0-9610-2F0D3246FE77

P698

Q30419537-6D29ECE7-D5DC-444F-A9C4-574527050D2C

P932

Q30419537-ED6622B0-64FE-43F4-8C9D-170853502C42

P356

P1433

Future Microbiology

P1476

Discovery and development of S ...... h a novel mechanism of action.

@en

P2093

Carol A Nacy

http://www.w3.org/2001/XMLSchema#string

Katherine A Sacksteder

http://www.w3.org/2001/XMLSchema#string

Koen Andries

http://www.w3.org/2001/XMLSchema#string

Marina Protopopova

http://www.w3.org/2001/XMLSchema#string

P2860

The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol

Design, synthesis, and evaluation of novel ethambutol analogues

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model

Metronidazole therapy in mice infected with tuberculosis

Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis

Antimycobacterial activities of riminophenazines

Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide

Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence

Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane

P304

823-837

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FMB.12.56

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Clifton E Barry

P577

2012-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230563826

http://www.w3.org/2001/XMLSchema#string

P698

22827305

http://www.w3.org/2001/XMLSchema#string

P932

3480206

http://www.w3.org/2001/XMLSchema#string